Ampio Pharma Shares Fall As FDA Rejects Proposed Change In Knee Osteoarthritis Trial
Ampio Pharmaceuticals Inc (NYSE: AMPE) received written responses from the FDA pursuant to a Type C meeting request regarding the AP-013 Phase 3 trial results.
Benzinga ·
Benzinga
